- For the University
- For external organisations
- Contact us
Our door is always open for an exploratory chat about how you might start a company or social enterprise.
In the interests of reducing spam, we have removed individual email addresses, but you are welcome to contact one of us directly by using firstname.lastname@example.org.
Our Seed Funds team can help you start a company or social enterprise.
As Head of Seed Funds at Cambridge Enterprise, Anne has overseen strong growth in our investment activities, with Seed Funds investing over £5 million each year in young companies.
Recent highlights include the purchase of Cambridge CMOS Sensors by ams, and the sale of Quethera to Astellas Pharma. Anne has also served on many boards including those of Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies, Psyomics, MorphoenIX and Quethera. She was a founding member of Praxis Auril, which supports Knowledge Exchange Commercialisation in the UK.
Anne’s early career includes experience in technology transfer at Imperial College Innovations Limited, in pharmaceutical development at Evans Medical, and in pharmaceutical product training at Information Transfer.
Anne holds a BSc in Medical Microbiology and a PhD in Immunology.
Anne joined the technology transfer team at the University of Cambridge in 2001, and has been involved with Cambridge Enterprise since its foundation in 2006, including as Interim Director just prior to this. She joined the Seed Funds team in 2008 and was appointed Head of Seed Funds in 2011.
As Head of Life Science investment, Christine has a focus on drug discovery with a broad portfolio of technologies, including University of Cambridge spin-outs Carrick, STORM, Z-factor, PhoreMost, Qkine and PolyProX. Christine was featured in BioBeat’s 50 Movers and Shakers in BioBusiness 2018.
Previously, Christine worked for six years in the Life Sciences Tech Transfer team managing licensing of University IP, including licences to Cambridge spin-outs Carrick, Storm and CEGX and managing the formation of the spin-out Z-factor. Christine also managed the University of Cambridge-GSK open innovation drug discovery initiative based at the SBC, working closely with academics to gain funding to develop translational projects.
Prior to that, she enjoyed 11 years working for Biotica, a biotechnology spin-out from the University of Cambridge as Department Director and Project Leader.
Christine has an MA and DPhil from the University of Oxford. She is the author of over 20 peer reviewed journal articles and over 20 patents. She was also the recipient of the Arthur E. Schwarting award for the best article published in the Journal of Natural Products in 2006.
Christine joined Cambridge Enterprise in September 2011.
Elaine is an Investment Director in the Seed Funds team, focusing on spin-out opportunities emerging from the physical sciences.
Since joining Cambridge Enterprise, she has spun-out nine new companies and worked on several follow-on funding rounds. She has held many director positions and currently sits on the boards of PervasID, Intellegens, Sorex, Xampla and CB2Tech as well as being an observer of Audiotelligence and Riverlane.
She has extensive experience in all stages of the investment process including due diligence, financial modelling, deal negotiation and investment management.
Elaine has worked in early-stage tech investing since 2001. At Dresdner Kleinwort Capital, she sourced new investment opportunities and managed the direct-investment portfolio for early-stage tech deals as well as leading on a £2bn fund of funds secondary sale. At PUK Ventures she focused on early-stage tech opportunities emerging from the public sector and UK universities.
Elaine has a BSc in Laser Physics and Optoelectronics (University of Strathclyde), a PhD in Physics (Optoelectronics Research Centre, University of Southampton) and qualified as a Chartered Accountant (ICAEW) in 2000.
Elaine Joined Cambridge Enterprise in December 2015.
Amanda is an Investment Director in the Seed Funds team at Cambridge Enterprise, focusing on spin out opportunities emerging from the life sciences.
Since joining Cambridge Enterprise she has worked with both the Technology Transfer and Seed Funds teams to build and support early stage companies who are accessing University technology. Amanda has spun out six new companies and worked on several follow-on funding rounds and exits.
She currently sits on the boards of PredictImmune Limited and Kalium Health Limited and previously served on the board of Sphere Fluidics Limited for six years. She has considerable experience in all stages of the investment process from deal sourcing to due diligence, deal negotiation, investment management and beyond.
Outside of Cambridge Enterprise, Amanda is Deputy Chair of the BBSRC Follow on Fund Committee.
Previously Amanda worked for Acambis as the UK Director of Business Development where she notably secured a Phase III out licensing agreement with Sanofi Pasteur and managed the sale of a business unit to Crucell. While working for the Wellcome Trust in a forerunner of the Innovations team, she served as the Wellcome Trust observer to the board for three start-up biotechnology companies.
Chris is an Investment Manager in the Seed Funds team focusing on spin-out opportunities emerging from the physical sciences.
Chris has spent over 15 years in UK high tech spin-outs and technology transfer. While Head of Engineering at CMR Fuel Cells in Cambridge, Chris led multi-disciplinary teams developing and delivering cleantech products to major multinational partners. He also co-founded Amalyst, a spin-out from University College London where, as Chief Technology Officer, he led its efforts in novel catalyst development for the energy transition. Chris joined UCL Business as a Senior Business Manager in 2016 where he helped commercialise a broad range of technologies from the physical sciences including the successful spin-out Bramble Energy.
Chris studied Chemical Engineering earning his BSc at the University of Tennessee with a magna cum laude distinction and his MSc from the University of South Carolina. He is passionate about the 21st century energy transition especially increasing hydrogen as an energy vector.
Chris joined Cambridge Enterprise in September 2020.
Fatima is a Senior Investment Associate in the Seed Funds team, whose focus is on early-stage life science spin-outs.
Fatima is a life sciences professional supporting academics at the University of Cambridge to develop technologies and build new companies to deliver socio-economic impact from research. With other Seed Fund team members, she works to help academics write business plans and build teams to successfully win pre-seed and seed investments.
Prior to joining Cambridge Enterprise, Fatima held a MRC Career Development Fellowship at the University of Oxford and went on to become a science translation ambassador. She has over 10 years’ experience in consultancy, technology transfer and management, having previously worked for Oxford University Innovation, Cancer Research Technology/CRUK and recently as commercialisation manager at the Babraham Institute in Cambridge.
Fatima holds a Biology degree from the University of Porto and a DPhil from the Medical Sciences division at the University of Oxford.
Fatima joined Cambridge Enterprise in March 2020.
James is an Investment Manager (Software) in the Seed Funds team, whose focus is on early-stage software spin-outs.
James works with teams both before and after they consider forming a company, assisting with the development of business plans and value propositions with a view to the team making applications and pitches for pre-seed and seed investments. James also attends the Board meetings of the University spin-out company Cambridge Touch Technologies as an Observer.
Prior to joining Cambridge Enterprise, James worked for a Cambridge-based software start-up for three years in a variety of internal and client-facing roles. Starting as an analyst delivering consultancy projects for clients, he progressed into account management while also contributing to sales, feature development and testing.
James holds a joint honours degree from the University of Cambridge, having studied Natural Sciences for three years and Management Studies at the Judge Business School for one year.
James joined Cambridge Enterprise in October 2017
Loukik is an Investment Associate in the Seed Funds team with a focus on early-stage life science spin-outs.
Prior to joining Cambridge Enterprise, Loukik has worked as project fellow in Indian Institute of Chemical Technology and as a freelance R&D consultant and technical content creator with several life science/biotech companies.
He has obtained a PhD in Medicine/Pharmacology from the National University of Singapore. During his PhD he also worked as an intern at the Asia Pacific Medical Technology Association (APACMed). He has recently finished his MSc in Entrepreneurship, Innovation and Technology management from Strathclyde Business School. Previously, he has done his Masters in Biomedical Science and Bachelors in Pharmacy from the University of Delhi.
Loukik joined Cambridge Enterprise in September 2021.
Cristina is an Investment Associate in the Seed Funds team.
Prior to joining Cambridge Enterprise, Cristina worked as a Technology Transfer Officer at the Barcelona Supercomputing Centre. Previously, she was a trainee at the European Patent Office within the Pan-European Seal Programme and also has experience as a R&D Consultant.
She has a Masters Degree in Environmental Engineering and a Bachelors Degree in Civil Engineering from the University of Valencia.
Cristina joined Cambridge Enterprise in December 2018.
Helen ensures that data relating to Seed Funds projects and investments is captured and updated effectively.
Prior to joining Cambridge Enterprise, Helen worked as a Data Coordinator in the Paediatric Intensive Care Unit at Addenbrooke’s hospital.
Helen has an MSc in Information Systems Design from Kingston University and a BSc in Psychology from Northumbria University.
Helen joined Cambridge Enterprise in July 2019.
Vicky job shares the role of PA to the Seed Funds team with Caroline Tann. Together they provide seamless PA and administrative support to the team.
Vicky is also a member of the company-wide Professional Assistants Team which provides a high level of personal, efficient and confidential admin support to Cambridge Enterprise.
Vicky is very involved with the organisation of the monthly Investment Committee meetings. She also assisted with the formation of the Professional Assistants Team and remains involved in the continuing development of this team.
Before joining Cambridge Enterprise, Vicky previously worked for the Physics Department in the University of Cambridge where she acted as PA to three senior staff and administrative support for the rest of the group. Prior to this, she was a PA to the Director of a regional building contractor and PA/Administrator to a computer consultancy firm.
Vicky holds an NVQ In Business Administration which she completed with a distinction.
Vicky joined Cambridge Enterprise in March 2017.
Caroline job shares the role of PA to the Seed Funds team with Vicky McDonnell.
Together with Vicky and Helen, Caroline provides admin support to the Head of Seed Funds and Investment Managers.
Caroline brings PA experience from a variety of areas of expertise prior to working at Cambridge Enterprise including property development, legal and neurology (Addenbrooke’s Hospital).
Caroline has an NVQ Level 3 in Administration and several secretarial achievements.
Caroline joined Cambridge Enterprise in April 2014.